난치성 포도막염에서 인플릭시맵 치료 결과

• 영문명: The Efficacy of Infliximab in Refractory Uveitis
• 발행기관: 대한안과학회
• 저자명: 김준형(Joon Hyung Kim) 이동욱(Dong Wook Lee) 조남천(Nam Chun Cho)
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume57,number1, 50~55쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2016.01.30

영문 초록

Purpose: To investigate the effectiveness of infliximab as treatment for refractory uveitis that recurred in spite of immunosuppressive agents. Methods: Thirty patients who were treated for refractory uveitis from 2002 to 2011 were included in this study. We retrospectively reviewed the medical records of 15 patients who were treated with Infliximab and 15 patients not treated with Infliximab. Infliximab was injected intravenously (5 mg/kg) 3 times every 4 weeks, and the patients were followed-up at 1 week, 2 weeks, and every month thereafter. Anterior chamber cell reaction with a score greater than 0.5+ was defined as recurrence of uveitis. Results: Among 15 patients treated with Infliximab, only one showed no response to the medication. The recurrence rate was significantly higher in patients receiving Infliximab treatment (1.1 ± 0.2 times) than in those not receiving Infliximab treatment (3.1± 0.3 times) (p=0.022). Conclusions: Infliximab can be used effectively on patients with refractory uveitis. However, a future prospective randomized study is needed to demonstrate the effectiveness of Infliximab and to determine an accurate protocol regarding dosage and number of injections

키워드

Infliximab Refractory uveitis TNF-α